Fertility Test Market
By Application (Male Fertility, Female Fertility),
By End Use (Home Care, Fertility Centers, Hospitals),
By Product (Ovulation Testing Kit, Fertility Monitors, Male Fertility Products),
By Mode of Purchase (OTC, Prescription, Online),
By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa):
Global Analysis and Forecast 2022-2032
The global fertility test market to be worth more than USD 1,468.32 million by 2032.
The market players have a significant opportunity because of rising fertility test sales online. One can purchase fertility testing equipment at nearby clinics. The devices can be bought without a prescription as they are over-the-counter products. Launching highly precise, technologically enhanced products would also fuel the market during the anticipated period. For instance, in March 2022, Posterity Health started Project AIM (Access to Care - Inclusion of the Male Partner). This multistate program gives men access to male fertility experts and at-home testing. Couples can become pregnant more quickly by including the male partner in fertility tests and advice from the beginning. Moreover, Patients can use a semen sample kit for at-home use or schedule a semen test at a convenient RMA of New York andrology facility through Project AIM. Men can also evaluate the findings and move on to a quick consultation for male infertility.
Due to changes in lifestyle and the development of technologically advanced technologies, the market for fertility testing may expand more quickly. Owing to this, technology advancements, including sonohysterogram, hysteroscopy, and hysterosalpingogram, numerous manufacturers can develop improved fertility testing devices with great accuracy. For instance, in June 2021, OvuFirst, a completely new patented sensor created to measure skin temperature, was launched by Fertility Focus, the makers of the OvuCore and OvuSense Pro family of top fertility monitoring solutions, with class II medical device classification and 510k FDA clearance.
According to the CXOs and primary research conducted, Women from various nations, including Australia, China, Denmark, Greece, India, the Netherlands, Spain, the United Kingdom, and the U.S., have recorded PCOS instances. Women are susceptible to PCOS throughout their lives. According to data from the PCOS Awareness Association (PCOSAA), approximately 5 million women in the United States have polycystic ovarian syndrome. The ovulation test kit may not produce accurate results because luteinizing hormone or estrogen levels are consistently high or show many peaks in PCOS. Thus, Polycystic Ovary Syndrome (PCOS), which causes women to ovulate sporadically due to the ovary's excessive estrogen production, is attributed to the market growth.
The fertility test market is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. In line with the analyzed region, the North American region will witness the highest market share, followed by Europe, Asia-Pacific, Latin America, and Middle East & Africa. High infertility rates among the populations, growing consumer awareness of fertility testing, and the presence of widely available fertility testing products are primary factors supporting market potential within the North American region. The major companies operating within the market are Abbott Laboratories, Advacare Pharma, bioMérieux SA, Church & Dwight Co. Inc., Fairhaven Health LLC, Fertility Focus Limited, Geratherm Medical AG, HiLin Life Products Inc., Procter & Gamble Co., Prestige Brands Holdings Inc., Quidel Corporation.